Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $72.00 price target on the stock.
Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)